Australia markets closed

ChemoCentryx, Inc. (CCXI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
25.61+0.55 (+2.19%)
At close: 04:00PM EST
24.60 -1.01 (-3.94%)
Pre-market: 08:12AM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 1.87B
Enterprise value 1.67B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)54.82
Price/book (mrq)5.91
Enterprise value/revenue 49.33
Enterprise value/EBITDA -14.41

Trading information

Stock price history

Beta (5Y monthly) 1.77
52-week change 3-56.81%
S&P500 52-week change 314.56%
52-week high 370.29
52-week low 39.53
50-day moving average 335.49
200-day moving average 324.98

Share statistics

Avg vol (3-month) 31.47M
Avg vol (10-day) 31.92M
Shares outstanding 570.03M
Implied shares outstanding 6N/A
Float 857.65M
% held by insiders 117.70%
% held by institutions 164.86%
Shares short (30 Dec 2021) 45.68M
Short ratio (30 Dec 2021) 44.11
Short % of float (30 Dec 2021) 411.98%
Short % of shares outstanding (30 Dec 2021) 48.11%
Shares short (prior month 29 Nov 2021) 44.92M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021


Profit margin 0.00%
Operating margin (ttm)-348.58%

Management effectiveness

Return on assets (ttm)-15.11%
Return on equity (ttm)-33.61%

Income statement

Revenue (ttm)34.27M
Revenue per share (ttm)0.49
Quarterly revenue growth (yoy)248.90%
Gross profit (ttm)-12.99M
EBITDA -116.93M
Net income avi to common (ttm)-121.1M
Diluted EPS (ttm)-1.74
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)269.43M
Total cash per share (mrq)3.85
Total debt (mrq)72.95M
Total debt/equity (mrq)23.09
Current ratio (mrq)4.89
Book value per share (mrq)4.52

Cash flow statement

Operating cash flow (ttm)-83.96M
Levered free cash flow (ttm)-91.6M